RNS Number : 2908W
Hikma Pharmaceuticals Plc
15 July 2024
 

London, 15 July 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its interim financial results for the six months ended 30 June 2024 on Thursday 8 August 2024.

A recording of the presentation will be available on the Group's website at www.hikma.com from 7:00am BST. Hikma will also hold a live Q&A conference call for analysts at 9:30am BST, and a recording will be made available on the Company's website.

 

To join via conference call please dial:

United Kingdom (Local): +44 20 3936 2999

United Kingdom (Toll-Free): +44 800 358 1035

Global Dial-In Numbers

Access Code: 229737

- ENDS -

Enquiries      

 

Hikma Pharmaceuticals PLC                                                                      

Susan Ringdal

EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 (0)7776 477050

Guy Featherstone

Director, Investor Relations                       

+44 (0)20 3892 4389/ +44 (0)7795 896738

Layan Kalisse

Senior Associate, Investor Relations                         

+44 (0)20 7399 2788/ +44 (0)7970 709912

 

 

Teneo (Press)                                               

Doug Campbell / Rob Yates

 

 

 

+44 (0)7753 136628/ +44 (0)7715 375443

                                                                                                       

 

 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2024 Hikma Pharmaceuticals PLC. All rights reserved.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORMZGMNKZFGDZM
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Hikma Pharmaceuticals Charts.